OBJECTIVES: Contrast-induced nephropathy (CIN) has not been systematically studied in high-risk patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). METHODS: We prospectively observed 515 consecutive patients with CKD undergoing PCI. Patients were divided into three groups: patients who underwent attempted PCI for CTO (group A, n = 85), patients who did not receive PCI for CTO (group B, n = 45) and patients without CTO (group C, n = 385). RESULTS: CIN developed in 55 patients (10.68 %). Group A patients received a larger CM dose than group B or group C (p = 0.024). The intravenous hydration volume, age and CIN Mehran score were not significantly different between the three groups. The incidence of CIN was 9.4 % for group A, 6.7 % for group B and 11.4 % for group C (p = 0.344). In-hospital mortality and required renal replacement therapy (p = 0.325) were not significantly different between the groups. Multivariate analysis showed that after adjusting for potential confounding factors, the odds ratio for CIN was 1.03 (p = 0.944) for group A and 0.64 for group B (p = 0.489) compared to group C. CONCLUSIONS: Attempts to achieve recanalization of CTO in patients with CKD might not increase the risk of CIN if appropriate preventative measures are taken. KEY POINTS: • Contrast-induced nephropathy can increase morbidity and mortality • Chronic kidney disease patients are at the greatest risk of CIN • Patients with CKD undergoing CTO-PCI are common • Incidence of CIN has not been reported in CKD patients • CTO-PCI in CKD patients might not increase the risk of CIN.
OBJECTIVES: Contrast-induced nephropathy (CIN) has not been systematically studied in high-risk patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). METHODS: We prospectively observed 515 consecutive patients with CKD undergoing PCI. Patients were divided into three groups: patients who underwent attempted PCI for CTO (group A, n = 85), patients who did not receive PCI for CTO (group B, n = 45) and patients without CTO (group C, n = 385). RESULTS:CIN developed in 55 patients (10.68 %). Group A patients received a larger CM dose than group B or group C (p = 0.024). The intravenous hydration volume, age and CIN Mehran score were not significantly different between the three groups. The incidence of CIN was 9.4 % for group A, 6.7 % for group B and 11.4 % for group C (p = 0.344). In-hospital mortality and required renal replacement therapy (p = 0.325) were not significantly different between the groups. Multivariate analysis showed that after adjusting for potential confounding factors, the odds ratio for CIN was 1.03 (p = 0.944) for group A and 0.64 for group B (p = 0.489) compared to group C. CONCLUSIONS: Attempts to achieve recanalization of CTO in patients with CKD might not increase the risk of CIN if appropriate preventative measures are taken. KEY POINTS: • Contrast-induced nephropathy can increase morbidity and mortality • Chronic kidney diseasepatients are at the greatest risk of CIN • Patients with CKD undergoing CTO-PCI are common • Incidence of CIN has not been reported in CKDpatients • CTO-PCI in CKDpatients might not increase the risk of CIN.
Authors: George Dangas; Ioannis Iakovou; Eugenia Nikolsky; Eve D Aymong; Gary S Mintz; Nicholas N Kipshidze; Alexandra J Lansky; Issam Moussa; Gregg W Stone; Jeffrey W Moses; Martin B Leon; Roxana Mehran Journal: Am J Cardiol Date: 2005-01-01 Impact factor: 2.778
Authors: Georgios Sianos; Gerald S Werner; Alfredo R Galassi; Michail I Papafaklis; Javier Escaned; David Hildick-Smith; Evald Høj Christiansen; Anthony Gershlick; Mauro Carlino; Angelos Karlas; Nikolaos V Konstantinidis; Salvatore D Tomasello; Carlo Di Mario; Nicolaus Reifart Journal: EuroIntervention Date: 2012-05-15 Impact factor: 6.534
Authors: Carlo Di Mario; Gerald S Werner; Georgios Sianos; Alfredo R Galassi; Joachim Büttner; Dariusz Dudek; Bernard Chevalier; Thierry Lefevre; Joachim Schofer; Jacques Koolen; Horst Sievert; Bernhard Reimers; Jean Fajadet; Antonio Colombo; Anthony Gershlick; Patrick W Serruys; Nicolaus Reifart Journal: EuroIntervention Date: 2007-05 Impact factor: 6.534
Authors: R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette K Wenger; R Scott Wright Journal: J Am Coll Cardiol Date: 2011-03-28 Impact factor: 24.094
Authors: Carlo Di Mario; David Hildick-Smith; Anthony Gershlick; Matteo Ghione; Pilar Agudo; Albert Alahmar; Alfredo Galassi; Gerald S Werner Journal: EuroIntervention Date: 2013-04-22 Impact factor: 6.534
Authors: Eugenia Nikolsky; Roxana Mehran; Diane Turcot; Eve D Aymong; Gary S Mintz; Zoran Lasic; Alexandra J Lansky; Emmanouil Tsounias; Jeffrey W Moses; Gregg W Stone; Martin B Leon; George D Dangas Journal: Am J Cardiol Date: 2004-08-01 Impact factor: 2.778
Authors: Shu Min Tao; Julian L Wichmann; U Joseph Schoepf; Stephen R Fuller; Guang Ming Lu; Long Jiang Zhang Journal: Eur Radiol Date: 2015-12-18 Impact factor: 5.315
Authors: Anna M Sailer; Patricia J Nelemans; Camille van Berlo; Ozan Yazar; Michiel W de Haan; Dominik Fleischmann; Geert Willem H Schurink Journal: Eur Radiol Date: 2015-10-02 Impact factor: 5.315